Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study
Source: View publication →
In this Phase 3 trial, subcutaneous lenacapavir administered twice-yearly demonstrated 100% efficacy in preventing HIV-1 infection among adolescent girls and young women in sub-Saharan Africa compared to a background HIV incidence rate.
Key Findings
Study Design
Study Limitations
Clinical Significance
This trial represents a potential paradigm shift in HIV prevention, providing a highly effective, long-acting, twice-yearly injectable option that could overcome the adherence challenges associated with daily oral PrEP, particularly for populations at high risk who face significant structural and social barriers.
Historical Context
For over a decade, daily oral F/TDF has been the standard of care for HIV pre-exposure prophylaxis. While effective when taken consistently, real-world adherence has been suboptimal for many high-risk groups. PURPOSE 1 marks the first successful pivotal trial of a six-month, long-acting subcutaneous agent, building on previous advancements in antiretroviral therapy and long-acting HIV injectable treatments.
Guided Discussion
High-yield insights from every perspective
What is the unique mechanism of action of lenacapavir compared to traditional antiretrovirals like tenofovir, and why does its pharmacokinetic profile allow for twice-yearly dosing?
Key Response
Lenacapavir is a first-in-class capsid inhibitor that disrupts the HIV-1 viral lifecycle at multiple stages, including capsid-mediated nuclear uptake, virus assembly, and capsid shell formation. Its high potency and extremely low solubility when administered subcutaneously result in a slow-release depot effect, providing sustained therapeutic concentrations for 26 weeks.
In the PURPOSE 1 trial, daily oral F/TAF did not show statistical superiority over the background HIV incidence, while lenacapavir showed 100% efficacy. How should this influence your clinical counseling regarding the 'adherence-effectiveness' gap in adolescent girls and young women?
Key Response
The trial highlights that while F/TAF is pharmacologically effective, its real-world efficacy is severely limited by adherence challenges in this demographic. Lenacapavir removes the daily burden of adherence, essentially bridging the gap between 'efficacy' (how it works in a lab) and 'effectiveness' (how it works in a person's life), making it a preferred choice for patients where daily pill-taking is a barrier.
The study utilized a recency-assay-derived 'counterfactual' background HIV incidence as the primary comparator. What are the implications of this trial design for evaluating the 'pharmacokinetic tail' and the potential for resistance emergence compared to long-acting cabotegravir?
Key Response
Because placebo-controlled trials are now unethical in many regions due to the existence of PrEP, counterfactual modeling is used. However, a major concern with long-acting agents is the 'tail'—the period where drug levels decline below the inhibitory threshold but remain high enough to select for resistance. While lenacapavir has a high genetic barrier, the 100% efficacy in this study means we have not yet seen how the virus escapes lenacapavir pressure in a PrEP-failure context, unlike the INSTI mutations seen with cabotegravir.
Given the 100% efficacy result, what are the broader systemic implications for HIV elimination goals, and how do we address the 'zero infections' paradox where a drug is so effective it becomes difficult to study its long-term resistance profile in the field?
Key Response
Lenacapavir represents a potential 'functional vaccine' for high-risk populations. The challenge for clinicians is that with zero breakthrough infections in the trial, we lack data on the specific mutational pathways of resistance in a PrEP setting. We must balance the excitement of high efficacy with the need for rigorous post-marketing surveillance to detect rare breakthroughs and understand the clinical management of the 'long tail' if patients miss doses.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
Critique the validity of using a cross-sectional HIV incidence estimate from the screening cohort (the counterfactual group) as a proxy for the randomized population. What statistical assumptions must hold for this comparison to be unbiased?
Key Response
The validity relies on the 'stationarity' of the epidemic and the assumption that the screening cohort is representative of the enrolled cohort's risk. Potential biases include the 'healthy volunteer effect' (where those who enroll have different behaviors than those who only screen) and the accuracy of the Mean Sleeping Time (MDRI) and False Recent Rate (FRR) parameters used in the recency assay formula to calculate incidence.
The PURPOSE 1 trial was stopped early by the Independent Data Monitoring Committee (IDMC). As an editor, what concerns would you have regarding the reporting of secondary endpoints, long-term safety, and the potential overestimation of effect size when a trial is terminated at an interim analysis?
Key Response
Early termination for benefit often leads to an inflation of the treatment effect and may leave the study underpowered for secondary safety endpoints or rare adverse events. Furthermore, stopping early limits our understanding of the durability of the twice-yearly regimen over several years, which is critical for a lifelong prevention strategy.
Current WHO and CDC guidelines recommend daily oral TDF/FTC or TAF/FTC and bimonthly CAB-LA for PrEP. Based on the PURPOSE 1 data, should lenacapavir be prioritized as a preferred first-line recommendation for cisgender women, and what implementation benchmarks are required before such a change?
Key Response
The 100% efficacy is superior to the historical performance of daily orals in this specific demographic. However, guidelines must consider the 'Implementation Gap'—including cost-effectiveness, the requirement for a healthcare provider to administer the injection every 6 months, and the need for validated HIV testing protocols to avoid starting lenacapavir during an undiagnosed acute infection, which could lead to multi-drug resistance.
Clinical Landscape
Noteworthy Related Trials
iPrEx Trial
Tested
Daily oral TDF/FTC
Population
MSM and transgender women at high risk for HIV
Comparator
Placebo
Endpoint
Incidence of HIV infection
PROUD Trial
Tested
Daily oral TDF/FTC
Population
MSM at high risk of HIV infection in the UK
Comparator
Deferred PrEP (delayed 12 months)
Endpoint
Confirmed HIV infection
HPTN 084 Trial
Tested
Injectable Cabotegravir every 8 weeks
Population
Adolescent girls and young women in sub-Saharan Africa
Comparator
Daily oral TDF/FTC
Endpoint
Incident HIV infection
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis